Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch the full video on Radcliffe Cardiology:

Dr Davide Cao (Icahn School of Medicine at Mount Sinai, US) discusses the key results and impact on clinical practice of the pre-specified analysis of the TWILIGHT trial presented at ESC Congress 2021.
TWILIGHT-HBR evaluated the effects of ticagrelor monotherapy versus ticagrelor (Brilinta) plus aspirin on bleeding and ischemic outcomes in a contemporary ARC-defined HBR population undergoing percutaneous coronary intervention (PCI).
The study showed that selected HBR patients who tolerated 3 months of DAPT with ticagrelor after PCI, withdrawing aspirin and continuing ticagrelor monotherapy for 1 year, significantly decreased clinically relevant as well as major bleeding events without compromising ischemic protection, as compared with ticagrelor plus aspirin.

Questions:
-The importance of TWILIGHT-HBR
-Study design and patient population
-Key results
-mpact on practice and influence on further research

Recorded remotely from New York, 2021.

Interviewer: Jordan Rance
Editor: Mirjam Boros

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.

Чтобы скачать видео "TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI | Dr Davide Cao" передвинте ползунок вправо